In addition, early use of genetically engineered T cells that recognize ALL epitopes (CAR T cells) will also provide an opportunity to improve the outcomes of these patients.31, 32, 33 Finally, incorporation of targeted kinase inhibitors to pediatric type chemotherapeutic regimens for specific subtypes of ALL such as BCR‐ABL like might further contribute to overcome the resistance to therapy and improve survival of this particularly difficult to treat subgroup of ALL patients. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.